Late Effects of Treatment in Survivors of Childhood Acute Myeloid Leukemia

Leung, Wing; Hudson, Melissa M.; Strickland, Donald K.; Phipps, Sean; Srivastava, Deo Kumar; Ribeiro, Raul C.; Rubnitz, Jeffrey E.; Sandlund, John T.; Kun, Larry E.; Bowman, Laura C.; Razzouk, Bassem I.; Mathew, Prasad; Shearer, Patricia; Evans, William E.; Pui, Ching Hon

doi:10.1200/jco.2000.18.18.3273

Cited by 191 publications

(130 citation statements)

References 33 publications

Supporting

Mentioning

120

Contrasting

Unclassified

Order By: Relevance

“…Few data have been published about long-term psychological problems in patients transplanted in childhood. Leung 11 reported academic difficulties in 14% of long-term survivors of childhood acute myeloblastic leukemia. Thompson 12 reported that 15-30% of children with chronic illness had significant behavioral problems.…”

Section: Discussionmentioning

confidence: 99%

Long-term outcomes after allogeneic stem cell transplantation for children with hematological malignancies

Ferry

Gemayel

Rocha

et al. 2007

Bone Marrow Transplant

111

View full text Add to dashboard Cite

We analyzed long-term outcomes and psycho-social aspects in 112 children with malignancies surviving 1 year after hematopoietic stem cell transplantation. At 10 years, overall survival was 7575%, TRM 1874% and relapse 1473%; 10-year cumulative incidence of infections was 3174%, cataract 4474%, pulmonary dysfunction 2074%, bone and joint complications 2975%, hypothyroidism 3674%, cardiac complications 1173% and secondary malignancies 773%. Total body irradiation (TBI) was the most significant risk factor associated with cataract, pulmonary impairment, osteoarticular complications and hypothyroidism. Chronic graft-versus-host disease was associated with higher incidence of pulmonary dysfunction. The number of complications per patient increased with time. Half of the patients had psychological disturbance, 13 signs of depression and 16 a history of eating behavior disorders; 54% of patients with one or more long-term complications had psychological problems. Sixty-nine patients had learning difficulties and 36 achieved normal scholarship. With increased follow-up, development of late effects and of psycho-social disturbance are of major concern. While the use of singledose TBI has now been abandoned, other risk factors are still of concern in the early 2000s.

show abstract

Section: Discussionmentioning

confidence: 99%

Long-term outcomes after allogeneic stem cell transplantation for children with hematological malignancies

Ferry

Gemayel

Rocha

et al. 2007

Bone Marrow Transplant

111

View full text Add to dashboard Cite

show abstract

“…110 Finally, the few data available about long-term cardiologic follow-up of patients after HD chemotherapy and HSC transplantation suggest that HD chemotherapy does not cause per se late development of cardiac toxicity, 5,79,90 although subclinical alteration of cardiac performance may last long. 50,90,109,[131][132][133][134] This is particularly important for the proportion of patients who may need a potentially cardiotoxic agent after HD chemotherapy for their relapsing disease. 135 …”

Section: Discussionmentioning

confidence: 99%

Cardiac toxicity of high-dose chemotherapy

Morandi

Ruffini

Benvenuto

et al. 2004

Bone Marrow Transplant

145

104

View full text Add to dashboard Cite

Summary:Cardiac toxicity is an uncommon but potentially serious complication of high-dose (HD) chemotherapy and little is known about incidence, severity and underlying mechanisms. We have systematically reviewed the literature of the last 30 years to summarize and appraise the published evidence on cardiac toxicity associated with HD chemotherapy. HD cyclophosphamide-containing regimens have been most commonly associated with cardiac toxicity, with a progressively decreasing incidence over time. Dosage, application regimens and coadministration of other chemotherapeutic agents emerged as risk factors. While cardiac toxicity has been rarely associated with other cytotoxic drugs, an unexpected incidence of severe cardiotoxicity resulted from reduced-intensity conditioning regimens containing melphalan and fludarabine. Predictive value of cardiologic examination of patients is limited, and patients with a slight depression of cardiac performance could tolerate HD chemotherapy. Clinical examination, resting electrocardiography and dosage adjustment in overweight patients remain the mainstay of prevention, with bidimensional echocardiography (2D echo) for patients with a history of anthracycline exposure. Strategies to decrease the long-term negative impact of anthracycline administration on cardiac performance are being investigated. New 2D echo-based techniques and circulating markers of cardiac function hold promise for allowing identification of patients at high risk for and early diagnosis of cardiac toxicity.

show abstract

“…Children and adolescents with primary multifocal, refractory, or relapsed malignant solid tumors still have a poor prognosis. Moreover, most cancer therapies are associated with signiWcant toxicity leading to long-term morbidity and an increased second malignancy rate [75,135]. Therefore, new treatment strategies are warranted.…”

Section: Introductionmentioning

confidence: 99%

Targets for active immunotherapy against pediatric solid tumors

Jacobs

Coulie

Figdor

et al. 2008

Cancer Immunol Immunother

View full text Add to dashboard Cite

The potential role of antibodies and T lymphocytes in the eradication of cancer has been demonstrated in numerous animal models and clinical trials. In the last decennia new strategies have been developed for the use of tumor-speciWc T cells and antibodies in cancer therapy. EVective anti-tumor immunotherapy requires the identiWcation of suitable target antigens. The expression of tumorspeciWc antigens has been extensively studied for most types of adult tumors. Pediatric patients should be excellent candidates for immunotherapy since their immune system is more potent and Xexible as compared to that of adults. So far, these patients do not beneWt enough from the progresses in cancer immunotherapy, and one of the reasons is the paucity of tumor-speciWc antigens identiWed on pediatric tumors. In this review we discuss the current status of cancer immunotherapy in children, focusing on the identiWcation of tumor-speciWc antigens on pediatric solid tumors.

show abstract

Late Effects of Treatment in Survivors of Childhood Acute Myeloid Leukemia

Abstract: Late sequelae are common in long-term survivors of childhood AML. Our findings should be useful in defining areas for surveillance of and intervention for late sequelae and in assessing the risk of individual late effects on the basis of age and history of treatment.

Cited by 191 publications

References 33 publications

Long-term outcomes after allogeneic stem cell transplantation for children with hematological malignancies

Long-term outcomes after allogeneic stem cell transplantation for children with hematological malignancies

Cardiac toxicity of high-dose chemotherapy

Targets for active immunotherapy against pediatric solid tumors

Contact Info

Product

Resources

About